文献速递中枢神经肿瘤放疗放疗物理与技术

基于失败模式分析评估胶质母细胞瘤标准放化疗中临床靶区缩小的可行性

Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis.
PubMed 文献 · Radiother Oncol · 2022-12-16

回顾性分析207例标准放化疗后复发的胶质母细胞瘤患者,按ESTRO指南以GTV外放2 cm生成CTV,分析失败模式;理论模拟GTV至CTV外放缩至1 cm,失败模式相似且正常脑与海马受照剂量显著降低,为未来临床试验评估靶区缩小提供依据。

要点

  • 207例复发胶质母细胞瘤中,180例野内复发、5例边缘复发、22例远处复发。
  • MGMT启动子甲基化者远处复发18.6%,未甲基化者6%(p=0.0046)。
  • 理论1 cm外放计划失败模式相似(野内177、边缘3、远处27),正常脑和海马剂量显著降低(p=0.0001)。

核心结论

  • 当前结果为进一步临床试验评估GTV至CTV外放缩小提供依据,目标是在维持标准放化疗生存获益的同时限制胶质母细胞瘤照射的认知后遗症。

研究设计与样本

  • 回顾性分析207例标准放化疗后复发的胶质母细胞瘤患者,按ESTRO靶区勾画指南以GTV(切除腔加残留肿瘤)外放2 cm生成CTV,用剂量体积直方图分析失败模式。
  • 为每例患者创建GTV至CTV外放缩小至1 cm的理论计划,比较失败模式和正常脑受照剂量。

主要发现

  • 自手术日期起中位总生存期15.3个月,中位无进展生存期7.8个月。
  • 复发为野内180例、边缘5例、远处22例。
  • 按MGMT启动子甲基化状态,远处复发见于甲基化肿瘤的18.6%和未甲基化肿瘤的6%(p=0.0046)。
  • 以1 cm缩小外放重新计划后,剂量学分析显示失败模式相似,野内、边缘和远处复发分别为177、3和27个计划,而健康脑和海马受照剂量较标准靶区勾画显著降低(p=0.0001)。

关键数值与推荐

  • 复发灶定义为:相交体积>80%包含在95%等剂量线内为野内,20-80%为边缘,<20%为远处。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze recurrence patterns in patients with glioblastoma (GBM) after standard chemoradiation according to different target volume delineation strategies. METHODS AND MATERIALS: Two hundred seven patients with GBM who recurred after standard chemoradiation were evaluated. According to ESTRO target volume delineation guideline, the CTV was generated by adding a 2-cm margin to the GTV, defined as the resection cavity plus residual tumor. Patterns of failure were analyzed using dose-volume histogram. Recurrent lesions were defined as in-field, marginal, or distant if > 80 %, 20-80 %, or < 20 % of the intersecting volume was included in the 95 % isodose line.For each patient, a theoretical plan consisting of reduced 1-cm GTV-to-CTV margin was created to compare patterns of failure and radiation doses to normal brain. RESULTS: Median overall survival and progression-free survival times were 15.3 months and 7.8 months, respectively, from the date of surgery. Recurrences were in-field in 180, marginal in 5, and distant in 22 patients. According to MGMT promoter methylation, distant recurrences occurred in 18.6 % of methylated and 6 % of unmethylated tumors (p = 0.0046). Following replanning with 1-cm reduced margin, dosimetric analysis showed similar patterns of failure. Recurrences were in-field, marginal, and distant in 177, 3, and 27 plans, respectively, although radiation doses to the healthy brain and hippocampi were significantly lower compared with standard target delineation (p = 0.0001). CONCLUSION: Current provide the rationale for evaluating GTV-to-CTV margin reduction in future clinical trials with the aim of limiting the cognitive sequelae of GBM irradiation while maintaining survival benefits of standard chemoradiation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Minniti G, Tini P, Giraffa M, et al. Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. Radiother Oncol. 2022. PMID: 36529439. doi:10.1016/j.radonc.2022.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。